The 5-D itch scale: a new measure of pruritus
2009/12/01 by Scott A. Elman, S. Elman, Linda S. Hynan +5 · 32 citations
Medicine · #Dermatology and Skin Diseases #Burn Injury Management and Outcomes #Wound Healing and Treatments
paper · doi:10.1111/j.1365-2133.2009.09586.x
Abstract
BACKGROUND: Itching is a subjective and multidimensional experience which is difficult to quantify. Most methodologies to assess itching suffer from being unidimensional, for example only measuring intensity without impact on quality of life, or only measuring scratching activity. None has actually been demonstrated to be able to detect change over time, which is essential to using them as an outcome measure of response to an intervention. The 5-D itch scale was developed as a brief but multidimensional questionnaire designed to be useful as an outcome measure in clinical trials. The five dimensions are degree, duration, direction, disability and distribution. OBJECTIVES: To study the 5-D with respect to validity, reliability and response to change. METHODS: The 5-D was administered to 234 individuals with chronic pruritus due to liver disease (n = 63), kidney disease (n = 36), dermatological disorders (n = 56), HIV/AIDS (n = 28) and burn injuries (n = 51). The 5-D was administered at baseline and after a 6-week follow-up period. A subset of 50 untreated patients was retested after 3 days to assess test-retest reliability. RESULTS: The 5-D score correlated strongly with a visual analogue score: r = 0.727 at baseline (P < 0.0001), r = 0.868 at the 3-day repeat (P < 0.0001), and r = 0.892 at the 6-week follow-up (P < 0.0001). There was no change in mean 5-D score between day 1 and day 3 in untreated individuals (intraclass correlation coefficient = 0.96, P < 0.0001). The 5-D did, however, detect significant changes in pruritus over the 6-week follow-up period (P < 0.0001). Subanalysis of the different patient groups revealed similar response patterns and scores, with the exception of lower total scores for the burn victims due to lower scores on the distribution domain because they itched only at the site of their burn. CONCLUSIONS: The 5-D, therefore, is a reliable, multidimensional measure of itching that has been validated in patients with chronic pruritus to able to detect changes over time. The 5-D should be useful as an outcome measure in clinical trials.
Cited by
- FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial
- Optimizing symptom management in people with kidney failure
- An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis
- The Experience of Itch in Autistic Adults: An Online Survey
- Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis of Randomized Controlled Trials
- European Guideline on Chronic Pruritus. In cooperation with the European Dermatology Forum (EDF)
- Methods to Validate Digital Health Technologies for Dermatology
- Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. [europepmc]
- Pruritus in Kidney Disease. [europepmc]
- The National Institute on Disability, Independent Living, and Rehabilitation Research Burn Model System: Twenty Years of Contributions to Clinical Service and Research. [europepmc]
- An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. [europepmc]
- Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study. [europepmc]
- Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A US Cross-Sectional Survey. [europepmc]
- Severity strata for five patient-reported outcomes in adults with atopic dermatitis. [europepmc]
- Burden of skin pain in atopic dermatitis. [europepmc]
- Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. [europepmc]
- A Comprehensive Conceptual Model of the Experience of Chronic Itch in Adults. [europepmc]
- NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. [europepmc]
- Measurement properties of three assessments of burden used in atopic dermatitis in adults. [europepmc]
- Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. [europepmc]
- A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. [europepmc]
- Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. [europepmc]
- Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. [europepmc]
- Secukinumab Therapy for Netherton Syndrome. [europepmc]
- Post-Burn Pruritus. [europepmc]
- CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management. [europepmc]
- Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. [europepmc]
- Internet-Delivered Cognitive Behavior Therapy for Atopic Dermatitis: A Randomized Clinical Trial. [europepmc]
- Itch: Epidemiology, clinical presentation, and diagnostic workup. [europepmc]
- Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. [europepmc]
- Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis. [europepmc]
- Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. [europepmc]
Related